X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
1. Omacor
2. Omega-3 Ethyl Ester 90
3. P-om3 Adjunct
1. 861006-80-6
2. Omacor
3. Coromega
4. Lotriga
5. Zodin
6. Ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate Compound With Ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate (1:1)
7. Omega-3 Acid Ethyl Esters
8. Omega-3-acid Ethyl Ester
9. Omega-3-acid Ethyl Esters
10. Chembl1200711
11. Tak-085
12. Omega-3-acid Ethyl Esters Type A
13. Icosapent (epa Ethyl Ester)
14. Doconexent (dha Ethyl Ester)
15. K-85
16. 4,7,10,13,16,19-docosahexaenoic Acid, Ethyl Ester, (4z,7z,10z,13z,16z,19z)-, Mixt. With (5z,8z,11z,14z,17z)-ethyl 5,8,11,14,17-eicosapentaenoate
17. Ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate
| Molecular Weight | 687.0 g/mol |
|---|---|
| Molecular Formula | C46H70O4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 31 |
| Exact Mass | 686.52741071 g/mol |
| Monoisotopic Mass | 686.52741071 g/mol |
| Topological Polar Surface Area | 52.6 Ų |
| Heavy Atom Count | 50 |
| Formal Charge | 0 |
| Complexity | 916 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 11 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Lovaza |
| Drug Label | LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a... |
| Active Ingredient | Omega-3-acid ethyl esters |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 1gm contains at least 900mg of the ethyl esters of omega-3 fatty acids |
| Market Status | Prescription |
| Company | Smithkline Beecham |
| 2 of 4 | |
|---|---|
| Drug Name | Omega-3-acid ethyl esters |
| Drug Label | LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a... |
| Active Ingredient | Omega-3-acid ethyl esters |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 1gm contains at least 900mg of the ethyl esters of omega-3 fatty acids |
| Market Status | Prescription |
| Company | Apotex; Teva Pharms Usa; Par Pharm |
| 3 of 4 | |
|---|---|
| Drug Name | Lovaza |
| Drug Label | LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a... |
| Active Ingredient | Omega-3-acid ethyl esters |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 1gm contains at least 900mg of the ethyl esters of omega-3 fatty acids |
| Market Status | Prescription |
| Company | Smithkline Beecham |
| 4 of 4 | |
|---|---|
| Drug Name | Omega-3-acid ethyl esters |
| Drug Label | LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a... |
| Active Ingredient | Omega-3-acid ethyl esters |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 1gm contains at least 900mg of the ethyl esters of omega-3 fatty acids |
| Market Status | Prescription |
| Company | Apotex; Teva Pharms Usa; Par Pharm |
Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (500 mg/dL) hypertriglyceridemia (HTG).
FDA Label
Omega-3-acid ethyl esters reduce triglyceride production, increase fatty acid metabolism, inhibit the release of fatty acids, increase triglyceride clearance, and decrease production of very low density lipoprotein cholesterol(VLDL-C).
Absorption
Omega-3-acid ethyl esters are rapidly hydrolysed to free fatty acids in the intestinal lumen which then become incorporated into phospholipids, cholesterol, and triglycerides so determination of bioavailability by serum concentration is not possible.
Route of Elimination
Includes oxidative catabolism to carbon dioxide and water
Volume of Distribution
82 56L
Clearance
757 mL/h 283mL/h.
Omega-3-acid ethyl esters are hydrolysed to free fatty acids in the intestinal lumen by pancreatic lipase. Once in enterocytes, the free fatty acids are packaged in chylomicrons which are released from cells into the circulation. Fatty acids then enter the liver where they can be incorporated into liver stores, incorporated into lipoprotein phospholipids, or oxidised for energy.
79 hours 47 hours.
Omega-3-acid ethyl esters reduce triglyceride production by the liver but this mechanism is not well understood. Omega-3-acid ethyl esters inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, reducing triglyceride synthesis and increasing paroxysmal beta-oxidation, which increases fatty aside metabolism. Omega-3-acid ethyl esters also inhibit the release of fatty acids by competing for enzymes involved in the synthesis of triglycerides, increase triglyceride clearance by increasing the activity of lipoprotein lipase, and decrease production of VLDL-C.
Market Place
